Compare · GLP-1 agonist
CagriSema vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| CagriSema | Semaglutide | |
|---|---|---|
| Evidence | Strong human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
CagriSema
CagriSema is one of the most heavily studied combination products in the obesity-drug pipeline, and also a useful case study in why "strong trial data" and "proven, approved, and better than the alternatives" are not the same thing. It is a once-weekly injectable that fixes two peptides into a…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most compounds we profile, the human evidence here is large, long, and consistent — so the honest job is to describe where it holds up and where it does not.